Suppression of amyloid deposition leads to long-term reductions in alzheimer's pathologies in Tg2576 mice

Journal of Neuroscience

Volumn 29, Issue 15, 2009, Pages 4964-4971

  Karlnoski, Rachel A ^a   Rosenthal, Arnon ^b   Kobayashi, Dione ^b   Pons, Jaume ^b   Alamed, Jennifer ^a   Mercer, Mary ^a   Li, Qingyou ^a   Gordon, Marcia N ^a   Gottschall, Paul E ^a   Morgan, David ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTIBODY; PROTEIN; DROSOPHILA PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE REPRESSION; HISTOLOGY; HYPOTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BRAIN; COMPARATIVE STUDY; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; PATHOLOGY; SENILE PLAQUE; TIME; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; BRAIN; DROSOPHILA PROTEINS; MICE; MICE, TRANSGENIC; SENILE PLAQUES; TIME FACTORS;

EID: 65549113533     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4560-08.2009     Document Type: Article

References (32)

1. Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D (2006) Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc 1:1671-1679. (Pubitemid 46773288)
2. Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque PA, Boussiquet-Leroux C, Churcher I, Atack JR, Harrison T, Shearman MS (2007) The novel gamma secretase inhibitor N-[cis-4-[(4- chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfbnamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 320:552-558. (Pubitemid 46147933)
3. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age-and region-dependent alterations in Abeta-degrading enzymes: Implications for Abeta-induced disorders. Neurobiol Aging 26:645-654. (Pubitemid 40228756)
4. Chauhan NB, Siegel GJ, Lichtor T (2004) Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Abeta antibody into the third ventricle of TgCRNDS mice. J Neurosci Res 78:732-741. (Pubitemid 39657590)
5. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sher-rington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Eraser P, St George Hyslop P, Selkoe DJ (1997) Mutant pre-senilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3:67-72. (Pubitemid 27019143)
6. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE (2001) Reduced effectiveness of Abetal-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22:721-727. (Pubitemid 33055611)
7. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527.
8. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW (2001) Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging 22:377-385. (Pubitemid 32510908)
9. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173:183-195. (Pubitemid 34151370)
10. Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, Gordon MN (2004) Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 190:245-253. (Pubitemid 39335723)
11. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100. (Pubitemid 28133087)
12. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-223.
13. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102. (Pubitemid 26332733)
14. Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC (2002) Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 70:493-500. (Pubitemid 35222386)
15. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is Abeta 42(43). Neuron 13:45-53. (Pubitemid 2122600)
16. Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR (2005) Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med 2:e355. (Pubitemid 43020991)
17. Jarrett JT, Lansbury PT Jr (1993) Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-1058. (Pubitemid 23180480)
18. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697. (Pubitemid 23162022)
19. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McCo-nlogue L (1997) Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 94:1550-1555. (Pubitemid 27087889)
20. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372-381. (Pubitemid 32107428)
21. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E (2007) Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27:627-633. (Pubitemid 46143766)
22. Kirschner DA, Inouye H, Duffy LK, Sinclair A, Lind M, Selkoe DJ (1987) Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A 84:6953-6957.
23. Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE (2006) Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid β40, and amyloid β42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 26:11923-11928.
24. Li Q, Gordon M, Cao C, Ugen KE, Morgan D (2007) Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci 8:22. (Pubitemid 46534761)
25. Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, Vigna SR, Vinters HV, Labenski ME, Mantyh PW (1992) Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci U S A 89:5462-5466.
26. Mann DM, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, Bird TD, Poorkaj P, Hardy J, Hutton M, Prihar G, Crook R, Rossor MN, Haltia M (1996) Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: Predominance of Abeta42(43). Ann Neurol 40:149-156. (Pubitemid 26274549)
27. McGowan E, Pickford F, Kim J, Onstead L, Erikson J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191-199.
28. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451:720-724.
29. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332. (Pubitemid 39061125)
30. Prior R, D'Urso D, Frank R, Prikulis I, Cleven S, Ihl R, Pavlakovic G (1996) Selective binding of soluble Abetal-40 and Abetal-42 to a subset of senile plaques. Am J Pathol 148:1749-1756. (Pubitemid 26170506)
31. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81:741-766. (Pubitemid 32267077)
32. Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R (2007) β-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer's disease pathogenesis. J Neurosci 27:3639-3649. (Pubitemid 46557686)